Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Cardinal Health support clinical drug trials by expanding PET Nuclear Pharmacy Services

Cardinal Health : 17 June, 2008  (Company News)
Cardinal Health is to begin manufacturing, compounding and distributing Positron Emission Tomography (PET) radiopharmaceuticals for clinical trials.
Cardinal Health owns and operates a network of more than 150 nuclear pharmacies and operates 25 cyclotron-based PET radiopharmaceutical manufacturing facilities. The facilities are registered with the Food and Drug Administration (FDA) to manufacture PET radiopharmaceuticals that are used by physicians to diagnose various medical conditions.

The company will now offer its PET manufacturing and distribution services to support clinical trials of new and novel PET agents. Cardinal Health will also work with pharmaceutical companies and physicians interested in using PET products to determine the efficacy of therapeutic medications.

'We're committed to advancing the future of molecular imaging by helping manufacturers expand the pipeline of new agents that will aid in the diagnosis and treatment of disease,' said John Rademacher, general manager of nuclear pharmacy services for Cardinal Health. 'By supporting the clinical trial phase of PET drug development, we will also build strong, long-term partnerships as these products move through the testing and approval phase and into routine clinical application.'

As part of its comprehensive service, Cardinal Health will also submit drug master files to the FDA for several of the PET agents it manufactures. These files contain detailed information about the manufacturing and storing of a specific drug and can help expand the use of PET products because they allow physicians and others in the pharmaceutical industry to test PET agents in the treatment or diagnosis of disease without needing to re-file drug manufacturing information with the FDA.

In addition to operating the largest radiopharmacy network in the USA, Cardinal Health is also the largest employer of nuclear pharmacists in the world. The combination of that nuclear pharmacy expertise and the size of its network allows Cardinal Health to reach more than 85 percent of all US hospitals within three hours and provide service and clinical expertise to the nuclear medicine community.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo